{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T08:56:00Z","timestamp":1781859360373,"version":"3.54.5"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006955","name":"Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006955","name":"Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006955","name":"Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006955","name":"Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017538","name":"DMC Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017538","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017302","name":"Barbara Ann Karmanos Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) are currently being used for treating breast cancer patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic diseases. Despite durable responses, almost all patients receiving PARPis ultimately develop resistance and succumb to their illness, but the mechanism of PARPi resistance is not fully understood. To better understand the mechanism of PARPi resistance, we established two olaparib-resistant SUM159 and MDA468 cells by chronically exposing olaparib-sensitive SUM159 and MDA468 cells to olaparib. Olaparib-resistant SUM159 and MDA468 cells displayed 5-fold and 7-fold more resistance over their corresponding counterparts. Despite defects in PARPi-induced DNA damage, these olaparib-resistant cells are sensitive to cisplatin-induced cell death. Using an unbiased proteomic approach, we identified 6 447 proteins, of which 107 proteins were differentially expressed between olaparib-sensitive and -resistant cells. Ingenuity pathway analysis (IPA) revealed a number of pathways that are significantly altered, including mTOR and ubiquitin pathways. Among these differentially expressed proteins, p62\/SQSTM1 (thereafter p62), a scaffold protein, plays a critical role in binding to and delivering the ubiquitinated proteins to the autophagosome membrane for autophagic degradation, was significantly downregulated in olaparib-resistant cells. We found that autophagy inducers rapamycin and everolimus synergistically sensitize olaparib-resistant cells to olaparib. Moreover, p62 protein expression was correlated with better overall survival in estrogen receptor-negative breast cancer. Thus, these findings suggest that PARPi-sensitive TNBC cells hyperactivate autophagy as they develop acquired resistance and that pharmacological stimulation of excessive autophagy could lead to cell death and thus overcome PARPi resistance.<\/jats:p>","DOI":"10.3389\/fonc.2022.908603","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T06:40:55Z","timestamp":1656484855000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Proteomic Analysis Identifies p62\/SQSTM1 as a Critical Player in PARP Inhibitor Resistance"],"prefix":"10.3389","volume":"12","author":[{"given":"Mohammed Hafiz","family":"Uddin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Pimentel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve M.","family":"Patrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seongho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malathy P.","family":"Shekhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gen Sheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/35021093","article-title":"Molecular Portraits of Human Breast Tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-0736-z","article-title":"Adjuvant Therapy of Triple Negative Breast Cancer","volume":"120","author":"Perez","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/GCO.0b013e3282f40de9","article-title":"Triple Negative Breast Cancer: Current Understanding of Biology and Treatment Options","volume":"20","author":"Kang","year":"2008","journal-title":"Curr Opin Obstet Gynecol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/PPO.0b013e3181d24ff7","article-title":"Triple-Negative Breast Cancer: Role of Specific Chemotherapy Agents","volume":"16","author":"Isakoff","year":"2010","journal-title":"Cancer J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200219060-00004","article-title":"Efficacy and Economics of Hormonal Therapies for Advanced Breast Cancer","volume":"19","author":"Simon","year":"2002","journal-title":"Drugs Aging"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2560","article-title":"Incidence and Outcome of Brca Mutations in Unselected Patients With Triple Receptor-Negative Breast Cancer","volume":"17","author":"Gonzalez-Angulo","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(Adp-Ribose) Polymerase Inhibition","volume":"66","author":"McCabe","year":"2006","journal-title":"Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.gde.2008.01.016","article-title":"DNA Repair Deficiency as a Therapeutic Target in Cancer","volume":"18","author":"Martin","year":"2008","journal-title":"Curr Opin Genet Dev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0526","article-title":"Poly (Adp-Ribose) Polymerase as a Novel Therapeutic Target in Cancer","volume":"16","author":"Annunziata","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous Recombination Deficiency (Hrd) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients With Triple-Negative Breast Cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1038\/s41467-020-16142-7","article-title":"Homologous Recombination DNA Repair Deficiency and Parp Inhibition Activity in Primary Triple Negative Breast Cancer","volume":"11","author":"Chopra","year":"2020","journal-title":"Nat Commun"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.214304","article-title":"P62-Mediated Phase Separation at the Intersection of the Ubiquitin-Proteasome System and Autophagy","volume":"131","author":"Danieli","year":"2018","journal-title":"J Cell Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.09.030","article-title":"P62 in Cancer: Signaling Adaptor Beyond Autophagy","volume":"167","author":"Moscat","year":"2016","journal-title":"Cell"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-019-0480-9","article-title":"Autophagy and Disease: Unanswered Questions","volume":"27","author":"Yang","year":"2020","journal-title":"Cell Death Differ"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.15698\/mic2016.12.546","article-title":"Autophagy: Machinery and Regulation","volume":"3","author":"Yin","year":"2016","journal-title":"Microb Cell"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.239566","article-title":"Bim Protein Degradation Contributes to Cisplatin Resistance","volume":"286","author":"Wang","year":"2011","journal-title":"J Biol Chem"},{"key":"B18","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1080\/15384101.2020.1723195","article-title":"Targeting Pp2a Inhibits the Growth of Triple-Negative Breast Cancer Cells","volume":"19","author":"Uddin","year":"2020","journal-title":"Cell Cycle"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/ng1097-141","article-title":"Killer\/Dr5 Is a DNA Damage-Inducible P53-Regulated Death Receptor Gene","volume":"17","author":"Wu","year":"1997","journal-title":"Nat Genet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2016.1203483","article-title":"Role for Dusp1 (Dual-Specificity Protein Phosphatase 1) in the Regulation of Autophagy","volume":"12","author":"Wang","year":"2016","journal-title":"Autophagy"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.225375","article-title":"Novel Role of Base Excision Repair in Mediating Cisplatin Cytotoxicity","volume":"286","author":"Kothandapani","year":"2011","journal-title":"J Biol Chem"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkt479","article-title":"Epistatic Role of Base Excision Repair and Mismatch Repair Pathways in Mediating Cisplatin Cytotoxicity","volume":"41","author":"Kothandapani","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09553002.2020.1851059","article-title":"Comet Assay Analysis of DNA Strand Breaks After Exposure to the DNA-Incorporated Auger Electron Emitter Iodine-125","author":"Unverricht-Yeboah","year":"2020","journal-title":"Int J Radiat Biol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"16787","DOI":"10.1038\/s41598-021-96340-5","article-title":"Survival Analysis in Breast Cancer Using Proteomic Data From Four Independent Datasets","volume":"11","author":"Osz","year":"2021","journal-title":"Sci Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01646-13","article-title":"Brca1 Pathway Function in Basal-Like Breast Cancer Cells","volume":"34","author":"Hill","year":"2014","journal-title":"Mol Cell Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-91442-8_15","article-title":"Olaparib","volume":"211","author":"Bochum","year":"2018","journal-title":"Recent results Cancer Res Fortschr der Krebsforschung Progres dans les recherches sur le Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt376","article-title":"Comparative Proteome Analysis Revealing an 11-Protein Signature for Aggressive Triple-Negative Breast Cancer","volume":"106","author":"Liu","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"B28","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13073-018-0602-x","article-title":"Integrated Proteotranscriptomics of Breast Cancer Reveals Globally Increased Protein-Mrna Concordance Associated With Subtypes and Survival","volume":"10","author":"Tang","year":"2018","journal-title":"Genome Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/ijms18091865","article-title":"Monitoring and Measuring Autophagy","volume":"18","author":"Yoshii","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.10.035","article-title":"Homeostatic Levels of P62 Control Cytoplasmic Inclusion Body Formation in Autophagy-Deficient Mice","volume":"131","author":"Komatsu","year":"2007","journal-title":"Cell"},{"key":"B31","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1002\/cncr.32600","article-title":"Poly(Adenosine Diphosphate Ribose) Polymerase Inhibitors Induce Autophagy-Mediated Drug Resistance in Ovarian Cancer Cells, Xenografts, and Patient-Derived Xenograft Models","volume":"126","author":"Santiago-O'Farrill","year":"2020","journal-title":"Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01238-0","article-title":"Targeting Autophagy Reverses De Novo Resistance in Homologous Recombination Repair Proficient Breast Cancers to Parp Inhibition","volume":"124","author":"Pai Bellare","year":"2021","journal-title":"Br J Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"4684","DOI":"10.1038\/s41467-020-18504-7","article-title":"Mtor-Mediated Cancer Drug Resistance Suppresses Autophagy and Generates a Druggable Metabolic Vulnerability","volume":"11","author":"Gremke","year":"2020","journal-title":"Nat Commun"},{"key":"B34","doi-asserted-by":"publisher","first-page":"ra27","DOI":"10.1126\/scisignal.aaa0899","article-title":"Phosphorylation of Eif2alpha Triggered by Mtorc1 Inhibition and Pp6c Activation Is Required for Autophagy and Is Aberrant in Pp6c-Mutated Melanoma","volume":"8","author":"Wengrod","year":"2015","journal-title":"Sci Signal"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2015.3604","article-title":"Parp-1 Promotes Autophagy Via the Ampk\/Mtor Pathway in Cne-2 Human Nasopharyngeal Carcinoma Cells Following Ionizing Radiation, While Inhibition of Autophagy Contributes to the Radiation Sensitization of Cne-2 Cells","volume":"12","author":"Chen","year":"2015","journal-title":"Mol Med Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2006.01.145","article-title":"Amp-Activated Protein Kinase Is a Positive Regulator of Poly(Adp-Ribose) Polymerase","volume":"342","author":"Walker","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"B37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/cancers12082054","article-title":"Parp Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies","volume":"12","author":"Lee","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2018.01.017","article-title":"Autophagy-Mediated Upregulation of Cytoplasmic Claudin 1 Stimulates the Degradation of Sqstm1\/P62 Under Starvation","volume":"496","author":"Kim","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"B39","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.ccell.2018.03.001","article-title":"Adipocyte P62\/Sqstm1 Suppresses Tumorigenesis Through Opposite Regulations of Metabolism in Adipose Tissue and Tumor","volume":"33","author":"Huang","year":"2018","journal-title":"Cancer Cell"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.05.004","article-title":"Metabolic Reprogramming of Stromal Fibroblasts Through P62-Mtorc1 Signaling Promotes Inflammation and Tumorigenesis","volume":"26","author":"Valencia","year":"2014","journal-title":"Cancer Cell"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/ncb0310-207","article-title":"P62, an Autophagy Hero or Culprit","volume":"12","author":"Rusten","year":"2010","journal-title":"Nat Cell Biol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.908603\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T06:40:58Z","timestamp":1656484858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.908603\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,29]]},"references-count":41,"alternative-id":["10.3389\/fonc.2022.908603"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.908603","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,29]]},"article-number":"908603"}}